Ligand News and Research

RSS

New glycan arrays discover autoimmunogenic activities of SARS-CoV

Researchers in New York City and Guangzhou, China applied the rapidly-developing carbohydrate microarray technology to study an inactivated SARS-coronavirus (SARS-CoV) vaccine and discovered autoimmunogenic activity of this newly identified human viral pathogen.

2 Aug 2004

Drug for multiple sclerosis prevented disease development when tested on animal models

Scientists from the Neurological Sciences Institute at Oregon Health & Science University have shown that an investigative drug for multiple sclerosis and related diseases prevented disease development when tested on animal models.

20 Jun 2004

Computational design used to engineer and construct a protein that could sense the nerve agent soman

Duke University Medical Center biochemists have used computational design to engineer and construct a protein that could sense the nerve agent soman. They said their achievement constitutes a proof-of principle that such engineered proteins can be made to detect nerve agents such as sarin and other toxic substances.

5 Jun 2004

Strategy to treat obesity through molecular liposuction

Researchers at The University of Texas M. D. Anderson Cancer Center have designed a strategy to treat obesity through “molecular liposuction.” The therapy destroys blood vessels supporting fat accumulation — causing the fat to rapidly break down and disappear.

10 May 2004

DakoCytomation has acquired exclusive worldwide rights to develop and commercialize pharmacogenomic diagnostic tests in the field of oncology

Human Genome Sciences, Inc. announced today a license agreement with DakoCytomation A/S (Glostrup, Denmark), under which DakoCytomation has acquired exclusive worldwide rights to develop and commercialize pharmacogenomic diagnostic tests in the field of oncology based on the TRAIL Receptor-1 (TRAIL-R1) and TRAIL Receptor-2 (TRAIL-R2) proteins.

31 Mar 2004